Eli Lilly is set to initiate a Phase III study of the GLP-1R/GIPR/GCGR agonist, semaglutide, in a head-to-head comparison.
I'm PortAI, I can summarize articles.
Recently, Eli Lilly registered a Phase III clinical trial for patients with type 2 diabetes on the clinicaltrials.gov website. The trial aims to evaluate the effectiveness and safety of retatrutide compared to semaglutide in the treatment of poorly controlled blood glucose. The study is expected to start on March 20th this year and last for approximately 26 months, with a projected enrollment of 1250 patients. In addition, Eli Lilly is also accelerating the Phase III TRIUMPH series of studies for retatrutide, which aims to evaluate its safety and effectiveness in the treatment of obesity, obstructive sleep apnea, and knee osteoarthritis.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments